Select Page

Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals

Jan Vollert, Esther Schenker, Malcolm Macleod, Anton Bespalov, Hanno Wuerbel, Martin Michel, Ulrich Dirnagl, Heidrun Potschka, Ann-Marie Waldron, Kimberley Wever, Thomas Steckler , Tom van de Casteele , Bruce Altevogt , Annesha Sil , Andrew S C Rice, EQIPD WP3 study group members
BMJ Open Sci. 2020 Apr 15. 4(1):e100046. doi: 10.1136/bmjos-2019-100046. eCollection 2020.

Transcriptional Assessment of Striatal mRNAs as Valid Biomarkers of Disease Progression in Three Mouse Models of Huntington’s Disease

Afshin Ghavami, Michael Olsen, Mei Kwan, Jose Beltran, John Shea, Sylvie Ramboz, Wenzhen Duan, Daniel Lavery, David Howland, Larry C Park
J Huntingtons Dis. 2020. 9(1):13-31. doi: 10.3233/JHD-190389.

The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models

Nicole K Polinski, Terina N Martinez, Sylvie Ramboz, Michael Sasner, Mark Herberth, Robert Switzer, Syed O Ahmad, Lee J Pelligrino, Sean W Clark, Jacob N Marcus, Sean M Smith, Kuldip D Dave, Mark A Frasier
Dis Model Mech 2022 Jun 1. 15(6):dmm049192. doi: 10.1242/dmm.049192. Epub 2022 May 25.

Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex

Lena H.Nguyen, Steven C.Leiser, Dekun Song, Daniela Brunner, Steven L.Roberds, Michael Wong, Angelique Bordey
Epilepsy Res. 2022 Mar. 181:106890. doi: 10.1016/j.eplepsyres.2022.106890. Epub 2022 Feb 18.

Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia

E. Leahy, M. Varney and D. Brunner
Phenotypic Drug Discovery. Chapter 10.

Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake

Bassem F. El-Khodor, Karma James, Qing Chang, Wei Zhang, Yvette R. Loiselle, Chinmayee Panda & Taleen Hanania
Nutr Neurosci. 2021 Nov 3;1-12. doi: 10.1080/1028415X.2021.1995119.

Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex

Theilmann W, Gericke B, Schidlitzki A, Anjum S, Borsdorf S, Harries T, Roberds S.L., Aguiar D, Brunner D, Leiser S, Song D, Fabbro D, Hillmann P, Wymann M, Loscher, W.
Neuropharmacology . 2020 Dec 1;180:108297. doi: 10.1016

Mouse model systems of autism spectrum disorder: Replicability and informatics signature

Kabitzke, P, Morales, D, He, D, Cox, K, Sutphen, J, Thiede, L, Sabath, E, Hanania, T, Biemans, B, Brunner, D.
Genes Brain Behav . 2020 Sep;19(7):e12676. doi: 10.1111

ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome

Kaufmann W E, Sprouse J, Rebowe N, Hanania T, Klamer D, Missling C U
Pharmacol Biochem Behav. 2019 Dec. 187:172796. doi: 10.1016/j.pbb.2019.172796